US$ 22.46
what is glp-1 receptor agonist Science Behind GLP 1 GIP and Glucagon Agonists for Obesity Research | News & Announcements GLP-1 receptor agonists and next-generation
Description
BCBS may cover Wegovy, but coverage varies by plan, and some dont cover weight loss medications

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

Here's what researchers found.

Mounting research suggests GLP-1 drugs, which are used to treat diabetes and obesity, may one day help people with alcohol use disorder

This is a huge market
